Skip to main content
    C

    Collegium Pharmaceutical Inc (COLL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $25.55
    +0.12 (+0.47%)

    Market Cap: $786.83M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Collegium Pharmaceutical Inc (COLL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Collegium Pharmaceutical (COLL) has a market cap of $786.83M and an enterprise value of $1.74B. Its net debt of $950.01M equals 120.74% of its market cap. Its trailing P/E of 3.7x is below its 5-year median of 6.2x.

    Total Valuation

    Enterprise value is 120.74% above the market cap, as debt exceeds cash.

    Market Cap$786.83M
    Enterprise Value$1.74B
    Latest price (Nov 17, 2026)$25.55

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 2.25% in the quarter ended Sep 30, 2026 and shrank 0.82% a year over 2 years.

    Shares Outstanding31.73M
    Shares Change (YoY)+0.51%
    Shares Change (QoQ)-2.25%
    Share Count Growth (2Y CAGR)-0.82%

    Valuation Ratios

    Sales and book value multiples are 1.0x and 2.7x. Its year-end P/E ranged from 4.4x to 82.3x from 2019 to 2025.

    P/E Ratio3.7x
    Forward P/E3.3x
    P/S Ratio1.0x
    Forward P/S0.9x
    P/B Ratio2.7x
    P/FCF Ratio2.4x
    P/OCF Ratio2.3x
    PEG Ratio0.5

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 4.9x EBITDA and 5.2x free cash flow.

    EV / Earnings45.5x
    EV / Sales2.1x
    EV / EBITDA4.9x
    EV / EBIT14.0x
    EV / FCF5.2x

    Price Statistics

    The stock is down 44.43% over 52 weeks and trades 10.51% above its 50-day average.

    Beta (1Y)0.15
    52-Week Change-44.43%
    1-Month Change+11.04%
    3-Month Change-11.10%
    6-Month Change-24.00%
    5-Year Change+21.24%
    10-Year Change+58.98%
    Total Return (1Y)-44.43%
    Total Return (3Y CAGR)+0.55%
    Total Return (5Y CAGR)+6.05%
    Return vs SPY (1Y)-55.21%
    Max Drawdown (1Y)-56.80%
    Max Drawdown (3Y)-56.80%
    Sharpe Ratio (1Y)-1.35
    Correlation with SPY (1Y)0.05
    50-Day Average$23.12
    200-Day Average$31.95
    52-Week Range$21.43 to $50.79
    RSI (14 Days)65.7
    Average Volume (20 Days)617.33K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.01x current liabilities, and total debt is 3.69x shareholder equity.

    Current Ratio1.01x
    Quick Ratio0.87x
    Debt / Equity3.69x
    Debt / EBITDA3.03x
    Debt / FCF3.26x
    Interest Coverage1.34x

    Returns and Efficiency

    Return on invested capital is 8.08% over the last 12 months, against a 5-year average of 7.98%.

    Return on Equity (ROE)12.88%
    Return on Assets (ROA)1.82%
    Return on Invested Capital (ROIC)8.08%
    Return on Capital Employed (ROCE)8.31%
    ROE (5Y Average)19.63%
    ROA (5Y Average)4.07%
    ROIC (5Y Average)7.98%
    Asset Turnover0.44x
    Inventory Turnover3.31x
    Receivables Turnover2.74x
    Cash Conversion Cycle233 days

    Taxes

    Income tax took 9.45% of pretax income over the last 12 months.

    Income Tax (TTM)$3.98M
    Effective Tax Rate9.45%

    Scores

    COLL has an Altman Z-Score of 0.81, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score0.81
    Altman Z ZoneDistress
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $815.19M over the last 12 months is up 7.68% from the 12 months before.

    Revenue$815.19M
    Revenue Growth (YoY)+7.68%
    Gross Profit$481.33M
    Operating Income$124.07M
    Pretax Income$42.15M
    Net Income$38.17M
    EBITDA$360.89M
    EBIT$124.07M
    Reported EPS (TTM)$6.89

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 14.12% of the $2.10B in total assets.

    Cash and Equivalents$144.80M
    Total Debt$1.09B
    Net Debt$950.01M
    Net Debt Per Share$29.94
    Working Capital$8.67M
    Shareholder Equity$296.44M
    Book Value Per Share$9.34
    Tangible Book Value-$1.03B
    Total Assets$2.10B
    Total Liabilities$1.80B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.73M of capital spending, operating cash flow left $336.29M of free cash flow.

    Operating Cash Flow$338.02M
    Capital Expenditures$1.73M
    Free Cash Flow$336.29M
    FCF Per Share$10.33
    Depreciation and Amortization$236.82M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 15.22%, against a 5-year average of 18.59%.

    Gross Margin59.05%
    Operating Margin15.22%
    Pretax Margin5.17%
    Net Margin4.68%
    EBITDA Margin44.27%
    EBIT Margin15.22%
    FCF Margin41.25%
    Gross Margin (5Y Average)55.24%
    Operating Margin (5Y Average)18.59%
    Net Margin (5Y Average)9.59%

    Growth

    Revenue grew 18.94% a year over 3 years, and EPS 32.87% a year.

    Revenue Growth (3Y CAGR)+18.94%
    Revenue Growth (5Y CAGR)+20.28%
    EPS Growth (3Y CAGR)+32.87%
    EPS Growth (5Y CAGR)+26.38%
    FCF Growth (3Y CAGR)+38.76%
    FCF Growth (5Y CAGR)+29.95%
    Operating Income Growth (3Y CAGR)+75.35%
    Book Value Per Share Growth (2Y CAGR)+27.47%

    Revenue and profit by year

    Dividends and Yields

    COLL does not pay a dividend. Its free cash flow yield is 41.48%.

    Earnings Yield27.03%
    FCF Yield41.48%
    Buyback Yield5.94%
    Shareholder Yield5.94%

    Peer Position

    Against 10 similar companies, COLL has the lowest P/E.

    P/E Ratio3.7x vs 11.8x median
    P/S Ratio1.0x vs 2.0x median
    ROIC8.08% vs 7.85% median
    Revenue Growth (Trailing 4 Quarters, YoY)+7.68% vs +15.08% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 4.21% and EPS growth at 0.13% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+4.21%
    EPS Growth Forecast (2Y CAGR)+0.13%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About COLL

    What is COLL's market cap?

    Collegium Pharmaceutical has a market cap of $786.83M. Its enterprise value, which adds debt and subtracts cash, is $1.74B.

    What is COLL's P/E ratio?

    Collegium Pharmaceutical has a trailing P/E ratio of 3.7x and a forward P/E of 3.3x.

    How many shares of COLL are outstanding?

    Collegium Pharmaceutical has 31.73M shares outstanding. The count is up 0.51% from a year earlier.

    Does COLL pay a dividend?

    No. Collegium Pharmaceutical does not pay a dividend.

    How much debt does COLL have?

    Collegium Pharmaceutical has $1.09B of total debt and $144.80M of cash and equivalents, a net debt position of $950.01M.